ArticleTelemedicine reports2025
Continuous Glucose Monitoring and Glycemic Control in an Adult Without Diabetes: Over 4,000 Automated Recordings Guide Contingency-Shaped Learning.
Article in Telemedicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterising the design and methods of continuous glucose monitoring used in behavioural interventions to inform future research in prediabetes.The Lancet. Digital health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The role of continuous glucose monitoring (CGM) in glycemic control among individuals without diabetes is not well understood. Specifically, the feedback generated may serve as a promising technology for obesity and lifestyle management among people without diabetes. In this case study, we used a CGM system to continuously measure sensor glucose levels in an adult female with BMI >30 without diabetes, capturing over 4,000 automated sensor recordings. The participant received real-time glucose readings via a smartphone app, which displayed values in a line graph. A shaded area indicated glucose levels exceeding the upper normoglycemic range, and an audio alert was triggered for high excursions (>140 mg/dL). We analyzed the percentage of daily time out of range (%TOR) across 16 days and evaluated whether standalone CGM feedback could reduce %TOR over the wear period. The participant reported checking the app multiple times per day every day. A notable reduction in average daily %TOR was observed, decreasing from 9.2% in the first sensor phase to 1.9% in the second. The median daily number of high-glucose excursions declined from 1.5 to 0.0. These findings suggest that standalone CGM offers feedback associated with glycemic control and can bring daily %TOR to under the recommended target of 5% in an individual with a metabolic risk but without diabetes. CGM may play a key role in obesity and lifestyle management by linking glucose tracking with behavior modification strategies, amplifying feedback necessary for contingency-shaped problem solving.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.